ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,187.67
0.00%
Dow Jones
39,056.39
0.44%
US Dollar vs MXN
16.908
0.01%
Brent Oil
83.56
0.84%
Bitcoin
61,339.93
-1.60%
Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Ligand Pharmaceuticals Incorporated (LGND)

  7. Ligand Pharmaceuticals Incorporated (LGND) Noticias

LGND

Ligand Pharmaceuticals (LGND)

Ligand Pharmaceuticals Incorporated
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:LGND
FechaHoraFuenteTítuloSímboloCompañía
07/03/202412:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/03/202417:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/03/202415:09Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/02/202415:49Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
27/02/202406:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:LGNDLigand Pharmaceuticals Incorporated
14/02/202405:26Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
13/02/202414:39Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
10/01/202418:30GlobeNewswire Inc.Henlius and Sermonix Announce Strategic Collaboration and Exclusive License Agreements for Novel Endocrine Therapy LasofoxifeneNASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/01/202416:40Dow Jones NewsLigand Pharmaceuticals Gets FDA OK for Viral Skin Infection TreatmentNASDAQ:LGNDLigand Pharmaceuticals Incorporated
01/12/202307:20GlobeNewswire Inc.Palvella Therapeutics and Ligand Pharmaceuticals Expand Strategic Partnership to Accelerate Phase 3 Development of QTORIN™ rapamycin for Microcystic Lymphatic Malformations and Additional High Unmet Need Clinical IndicationsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
28/11/202308:01GlobeNewswire Inc.Sermonix Pharmaceuticals Announces Five Abstracts Accepted for Presentation at 2023 San Antonio Breast Cancer SymposiumNASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/11/202320:48Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/11/202316:03Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LGNDLigand Pharmaceuticals Incorporated
06/11/202308:00GlobeNewswire Inc.Sermonix Pharmaceuticals Announces JCO Precision Oncology Publication of Case Report on a Complete Remission in a Metastatic Breast Cancer Patient Participating in ELAINE-1 TrialNASDAQ:LGNDLigand Pharmaceuticals Incorporated
18/10/202307:00GlobeNewswire Inc.Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026NASDAQ:LGNDLigand Pharmaceuticals Incorporated
02/10/202308:00GlobeNewswire Inc.Sermonix Pharmaceuticals Shares Results of EQUALS 2 Survey on Vaginal and Sexual Health in Patients with ER+/HER2- Metastatic Breast CancerNASDAQ:LGNDLigand Pharmaceuticals Incorporated
25/09/202317:12Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:LGNDLigand Pharmaceuticals Incorporated
17/07/202307:45GlobeNewswire Inc.Novan Enters into Agreement to Sell Substantially All of its Assets, including Berdazimer Gel, 10.3% (SB206), and Files for Chapter 11 ProtectionNASDAQ:LGNDLigand Pharmaceuticals Incorporated
29/06/202308:00GlobeNewswire Inc.Sermonix Pharmaceuticals to Present Two Posters at The Menopause Society 2023 Annual MeetingNASDAQ:LGNDLigand Pharmaceuticals Incorporated
21/06/202308:29Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
09/06/202316:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
05/06/202308:01GlobeNewswire Inc.Sermonix Pharmaceuticals Shares ASCO Poster Presentation on Longer Patient Follow-up Results for ELAINE-2 Study in ESR1-mutated Metastatic Breast CancerNASDAQ:LGNDLigand Pharmaceuticals Incorporated
25/05/202316:00GlobeNewswire Inc.Sermonix Pharmaceuticals to Share Longer Patient Follow-up Results for ELAINE-2 in Poster Presentation at ASCO 2023NASDAQ:LGNDLigand Pharmaceuticals Incorporated
16/05/202312:15Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
08/05/202315:08Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
26/04/202311:25Edgar (US Regulatory)Confidential Treatment Order (ct Order)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202315:10Edgar (US Regulatory)Annual Report to Security Holders (ars)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202315:08Edgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
20/04/202315:08Edgar (US Regulatory)Proxy Statement (definitive) (def 14a)NASDAQ:LGNDLigand Pharmaceuticals Incorporated
22/02/202315:01Business WireLigand Reports Fourth Quarter and Full Year 2022 Financial ResultsNASDAQ:LGNDLigand Pharmaceuticals Incorporated
 Showing the most relevant articles for your search:NASDAQ:LGND

Su Consulta Reciente

AMEX
XLE
Energy Select Sector SPDR
NASDAQ
AAPL
Apple
USI
USTECH100
US Tech 100
CCOM
US30
US 30
USOTC
BNPQY
BNP Paribas (QX)
NASDAQ
GOOGL
Alphabet
NYSE
NKE
Nike
NYSE
MCD
McDonalds
NYSE
AXP
American Express
NYSE
XOM
Exxon Mobil
COIN
ETHUSD
Ethereum
CCOM
US500
US 500
FX
USDMXN
US Dollar vs MXN
NYSE
VZ
Verizon Communications
NASDAQ
QQQ
Invesco QQQ Trust Series 1
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados